Molecular Genetic Approaches in the Therapy of Alzheimer’s Disease

  • Ezio Giacobini
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 265)


Definitive treatment of Alzheimer’s disease (AD) will depend upon understanding the etiology and pathogenesis of this degenerative process. Techniques derived from studies of molecular genetics will identify individuals at high risk [1]. These studies may also characterize the molecular defect(s) derived from the genetic expression of the disease, but we view them as future developments without clinical application for 1 to 2 decades. Alternatively, a shorter-term progress in the understanding of basic alterations of neurotransmitters, neuromodulators and growth factors may lead to the development of ameliorative or palliative therapies that attenuate the expression of symptoms and possibly even slow the disease process [2].


Nerve Growth Factor Alzheimer Disease Amyloid Protein Precursor Neuritic Plaque Amyloid Formation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R.N. Rosenberg. Neurogenetics, Principles, and Practice. Raven Press, NY, Alzheimer’s disease, pp. 95–99 (1986).Google Scholar
  2. 2.
    E. Giacobini and R. Becker. 1988. Advances in therapy of Alzheimer’s disease. In: Familial Alzheimer’s Disease: Molecular Genetics, Clinical Perspectives, a Promising New Research. eds.G. Miner, J. Blass, R. Richter & J. Valentine. Marcel Dekker, Inc. New York (In press )Google Scholar
  3. 3.
    R.D. Terry, L.A. Hansen, R. DeTeresa et al. Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J. Neurophathol. Exp. Neurol. 46, 262–268 (1987).CrossRefGoogle Scholar
  4. 4.
    R. Katzman, R. Terry, R. DeTeresa, T. Brown, P. Davies, P. Fuld, X. Renbing and A. Peck. Clinical, pathological and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23, 138–144 (1988).CrossRefGoogle Scholar
  5. 5.
    H.M. Wisniewski, G.S. Merz and R.I. Carp. Current hypothesis of the etiology and pathogenesis of senile dementia of the Alzheimer type. Interdiscipl. Topics Geront. 19, 45–53 (1985).Google Scholar
  6. 6.
    R.D. Terry. What, where and why are plaques. Alzheimer Disease and Associated Disorders 2: 223 (1988).CrossRefGoogle Scholar
  7. 7.
    R.N. Rosenberg. Molecular genetics of Alzheimer’s disease; recent advances. Proceedings of the International Symposium on Alzheimer’s disease Abst., Kuopio, Finland (June, 1988 ).Google Scholar
  8. 8.
    D.A. Lewis, G.A. Higgins, W.G. Young, D. Goldgaber, D.C. Gajdusek, M.C. Wilson and J.H. Morrison. Distribution of precursor amyloid-0-protein messenger RNA in human cerebral cortex: Relationship to neurofibrillary tangles and neuritic plaques. Proc. Natl. Acad. Sci 85, 1691–1695 (1988).CrossRefGoogle Scholar
  9. 9.
    M.R. Palmert, T.E. Golde, M.L. Cohen, D.M. Kovacs, R.E. Tanzi, J.F. Gusella, M.F. Usiak, L.H. Youngkin and S.G. Youngkin. Amyloid protein precursor messenger RNAs; differential expression in Alzheimer’s disease. Science, Vol. 241, pp. 1080–1084 (1988).CrossRefGoogle Scholar
  10. 10.
    R.E. Tanzi, A.I. McClatchey, E.D. Lamperti, L. Villa-Komaroff, J.F. Gusella, R.L. Neve. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature, 528–530 (1988).Google Scholar
  11. 11.
    N. Kitaguchi, Y. Takahashi, Y. Tokushima, S. Shiojiri and H. Ito. Novel precursor of Alzheimer’s disease amyloid protein shows protease inhibitory activity. Nature 331, 530–532 (1988).CrossRefGoogle Scholar
  12. 12.
    R.E. Tanzi, J.F. Gusella, P.C. Watkins, G.A. Bruns, P. St. George-Hyslop, M.L. VanKeuren, D. Patterson, S. Pagan, D.M. Kurnit and R.L. Neve. Amyloid ß protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer ocus. Science 235, 880–884 (1987).CrossRefGoogle Scholar
  13. 13.
    G. Bruce and G. Heinrich. The construction of human NGF expression vectors: Their potential role in the treatment of Alzheimer disease. 18th Annual Meeting Society for Neuroscience. Abst 331. 17 pp 827. (1988).Google Scholar
  14. 14.
    L. Olson, P. Enfors, T. Ebendal, P. Mouton, I. Stromberg and H. Persson. The establishment and use of stable cell lines that overexpress a transfected ß-NGF gene with studies in vitro, in oculo and intracranially. 18th Annual Meeting Society for Neuroscience Abst 276. 6 pp 684. (1988).Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Ezio Giacobini
    • 1
  1. 1.Department of PharmacologySouthern Illinois University, School of MedicineSpringfieldUSA

Personalised recommendations